Protein kinase C β inhibition: the promise for treatment of diabetic nephropathy

@article{Anderson2007ProteinKC,
  title={Protein kinase C $\beta$ inhibition: the promise for treatment of diabetic nephropathy},
  author={P. W. Anderson and J. McGill and K. Tuttle},
  journal={Current Opinion in Nephrology and Hypertension},
  year={2007},
  volume={16},
  pages={397–402}
}
Purpose of reviewThe prevalence of diabetes mellitus is increasing rapidly worldwide. The number of patients with diabetic nephropathy is also expected to increase considerably in the future despite currently available treatments that may prevent or slow kidney disease progression. Additional therapeutic agents are therefore urgently needed. Recent findingsRuboxistaurin mesylate is a bisindolylmaleimide that specifically inhibits the β-isoform of protein kinase C. In animal models of diabetic… Expand
Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease
Renal and Vascular Mechanisms of Thiazolidinedione-Induced Fluid Retention
PKCβ/NF-κB pathway in diabetic atrial remodeling.
High glucose-induced RhoA activation requires caveolae and PKCβ1-mediated ROS generation.
PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells.
...
1
2
...

References

SHOWING 1-10 OF 45 REFERENCES
Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
  • D. Koya, M. Haneda, +9 authors R. Kikkawa
  • Medicine
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2000
...
1
2
3
4
5
...